Monthly Archives: November 2012
Sanofi would like to assure you that this out-of-stock situation of Sofradex® is temporary and at present, we are actively and earnestly endeavouring to make sure that we will have stock of Sofradex® 8ml available as soon as possible to prevent any further disruption and inconvenience. Should you have any further queries, please contact our Customer Services Department on our tollfree line 0800 601 228.
Seroquel XR 150mg® is now launched and is indicated as adjunctive therapy in the treatment of resistant major depressive disorder. It should be administered once daily in the evening, with or without food, and swallowed whole and not split, chewed or crushed.
The initial dose for major depressive disorder should begin at 50mg on Day 1 and 2, increased to 150mg on Day 3 and 4. Further adjustments can be made upwards or downwards within the recommended dose range of 50-300mg depending upon the clinical response and tolerability of the patient.
Seroquel XR offers a treatment option for: schizophrenia, mania and depression in bipolar disorder; major depressive disorder (MDD).
For any Medical queries: 011 797 6000 or SA.MEAMedinfo@astrazeneca.com
It contains dry ivy leaf extract (Hedera Helix) that has expectorant and spasmolytic actions. It is indicated for: Acute inflammation of the respiratory tract and for the improvement of symptoms of chronic-inflammatory bronchial disease. SEP price incl VAT is R45.00
MSD has launched of JANUVIA® (25 mg, 50 mg, 100 mg daily), a new oral antidiabetic agent for the treatment of type 2 diabetes.
JANUVIA® contains sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor (incretin enhancer) that increases the levels of two incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). These hormones play a major physiological role in maintaining glucose homeostasis.
Sitagliptin is the most widely prescribed DPP-4 inhibitor worldwide, with over 46 million prescriptions dispensed for the sitagliptin family. JANUVIA® has been launched in 107 countries and boasts clinical data of up to 2 years in duration. Sitagliptin in combination with metformin has a lower risk of hypoglycaemia and leads to weight loss versus a sulphonylurea plus metformin.
Should you have any further queries please contact Sarojini Moodley (Diabetes Franchise Brand and Customer Manager):
(011) 655 3117
Novartis South Africa is pleased to announce the introduction of Galvus®Met effective from 17 October 2012. This is in addition to the Galvus® range, enhancing their metabolic portfolio.
Here are the Galvus®Met options: Galvus Met 50mg/850mg tablets in 30’s and 60’s Galvus Met 50mg/1000mg tablets in 30’s and 60’s